| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 55111-0646-30 | 55111-0646 | Letrozole | Letrozole | 2.5 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jun 3, 2011 | In Use | ||
| 67877-0538-07 | 67877-0538 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Apr 28, 2017 | In Use | |
| 61919-0087-10 | 61919-0087 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Aug 29, 2019 | In Use | |
| 70518-2650-00 | 70518-2650 | Ondansetron | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Mar 25, 2020 | In Use | |
| 72579-0121-01 | 72579-0121 | Tislelizumab, Tislelizumab-jsgr | TEVIMBRA | 10.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-1 | Intravenous | Mar 14, 2024 | In Use | |
| 70771-1676-07 | 70771-1676 | LENALIDOMIDE | LENALIDOMIDE | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Mar 7, 2023 | In Use | |
| 83980-0013-13 | 83980-0013 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 19, 2025 | In Use | |
| 59572-0502-00 | 59572-0502 | Pomalidomide | Pomalyst | 2.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 18, 2013 | In Use | |
| 17856-0691-07 | 17856-0691 | Ondansetron | Ondansetron | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 17, 2024 | In Use | |
| 16590-0545-30 | 16590-0545 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 27, 2009 | In Use | |
| 63187-0382-60 | 63187-0382 | Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 10.0 mg/1 | Hormonal Therapy | Progestin | Oral | Sep 1, 2016 | In Use | ||
| 52959-0126-30 | 52959-0126 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jul 12, 2002 | In Use | |
| 63629-5269-03 | 63629-5269 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan 26, 2016 | In Use | ||
| 51655-0355-26 | 51655-0355 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 28, 2020 | In Use | |
| 57962-0007-12 | 57962-0007 | Ibrutinib | Imbruvica | 70.0 mg/mL | Chemotherapy | Tyrosine Kinase Inhibitor | Bruton's Tyrosine Kinase (Btk) /BCR | Oral | Aug 24, 2022 | In Use | |
| 69238-1255-03 | 69238-1255 | Isotretinoin | Isotretinoin | 20.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Oct 10, 2025 | In Use | |
| 71288-0164-50 | 71288-0164 | Leucovorin calcium | Leucovorin calcium | 500.0 mg/50mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | Jul 19, 2023 | In Use | |
| 80425-0074-02 | 80425-0074 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Sep 16, 2020 | In Use | |
| 00781-2691-44 | 00781-2691 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 12, 2013 | In Use | |
| 62135-0490-30 | 62135-0490 | Anastrozole | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Jan 17, 2022 | In Use | ||
| 63187-0561-30 | 63187-0561 | Dexamethasone | Dexamethasone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct 1, 2015 | In Use | |
| 67157-0111-05 | 67157-0111 | Hydroxyprogesterone Caproate | Hydroxyprogesterone Caproate | 250.0 mg/mL | Hormonal Therapy | Progestin | Intramuscular | In Use | |||
| 24979-0725-06 | 24979-0725 | Anastrozole Tablets | Anastrozole | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Mar 21, 2025 | In Use | ||
| 70709-0155-10 | 70709-0155 | Dasatinib | PHYRAGO | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Sep 22, 2025 | In Use | |
| 68084-0075-21 | 68084-0075 | Tretinoin | Tretinoin | 10.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Jul 18, 2013 | In Use |
Found 12611 results — Export these results
Home